Skip to main content

Volume 14 Supplement 1

Proceedings of Delivery Systems and Current Strategies to Drug Design


Edited by Reinaldo Acevedo, Mario Landys, Armando Acosta, Herve Bercovier, Mohd Nor Norazmi, Valerie Ferro and Maria Elena Sarmiento

Funding of this supplement was supported by Universiti Sains Malaysia, Malaysia and Instituto Finlay, Cuba

Second International Congress on Immunopharmacology 2011. Go to conference site.

Varadero Beach, Cuba26-30 June 2011

  1. The development of molecules specific for M. tuberculosis-infected cells has important implications, as these tools may facilitate understanding of the mechanisms regulating host pathogen interactions in vivo. In...

    Authors: Frank Camacho, Jim Huggett, Louise Kim, Juan F Infante, Marco Lepore, Viviana Perez, María E Sarmiento, Graham Rook and Armando Acosta
    Citation: BMC Immunology 2013 14(Suppl 1):S2
  2. Immunoglobulin A is the most abundant isotype in secretions from mucosal surfaces of the gastrointestinal, respiratory and genitourinary tracts and in external secretions such as colostrum, breast milk, tears ...

    Authors: Nadine Alvarez, Oscar Otero, Frank Camacho, Reinier Borrero, Yanely Tirado, Alina Puig, Alicia Aguilar, Cesar Rivas, Axel Cervantes, Gustavo Falero-Díaz, Armando Cádiz, María E Sarmiento, Mohd Nor Norazmi, Rogelio Hernández-Pando and Armando Acosta
    Citation: BMC Immunology 2013 14(Suppl 1):S3
  3. The use of new adjuvants in vaccine formulations is a subject of current research. Only few parenteral adjuvants have been licensed. We have developed a mucosal and parenteral adjuvant known as AFCo1 (Adjuvant...

    Authors: Caridad Zayas, Domingo González, Reinaldo Acevedo, Judith del Campo, Miriam Lastre, Elizabeth González, Belkis Romeu, Maribel Cuello, Julio Balboa, Osmir Cabrera, Luisa Guilherme and Oliver Pérez
    Citation: BMC Immunology 2013 14(Suppl 1):S4
  4. Recombinant Mycobacterium bovis bacille Calmette–Guèrin (rBCG) expressing three T cell epitopes of Mycobacterium tuberculosis (MTB) Ag85B antigen (P1, P2, P3) fused to the Mtb8.4 protein (rBCG018) or a combinatio...

    Authors: Rohimah Mohamud, Maryam Azlan, Daniel Yero, Nadine Alvarez, Maria E Sarmiento, Armando Acosta and Mohd-Nor Norazmi
    Citation: BMC Immunology 2013 14(Suppl 1):S5
  5. An in silico study was carried out to identify antigens for their possible collective use as vaccine candidates against diseases caused by different classes of pathogenic mycobacteria with significant clinical...

    Authors: Bárbara de la Caridad Addine Ramírez, Reynel Marrón, Rommel Calero, Mayelin Mirabal, Juan Carlos Ramírez, María E Sarmiento, Mohd Nor Norazmi and Armando Acosta
    Citation: BMC Immunology 2013 14(Suppl 1):S6
  6. The only currently available vaccine against tuberculosis (TB) is Mycobacterium bovis Bacille Calmette-Guerin (BCG), which has inconsistent efficacy to protect against the disease in adults. M. tuberculosis (MTB)...

    Authors: Fátima Reyes, Yanely Tirado, Alina Puig, Reinier Borrero, Giselle Reyes, Sonsire Fernández, José Luis Pérez, Ramlah Kadir, Caridad Zayas, Mohd Nor Norazmi, María E Sarmiento and Armando Acosta
    Citation: BMC Immunology 2013 14(Suppl 1):S7
  7. Whooping cough remains a health problem despite high vaccination coverage. It has been recommended that development of new strategies provide long-lasting immunity. The aim of this work was to evaluate the pot...

    Authors: Sonsire Fernández, Esther M Fajardo, Aleida Mandiarote, Gemma Año, Maria A Padrón, Michel Acosta, Rubén A Cabrera, Luis A Riverón, Maydelis Álvarez, Kirenia Blaín, Mildrey Fariñas, Daniel Cardoso, Luis G García, Concepción Campa and José L Pérez
    Citation: BMC Immunology 2013 14(Suppl 1):S8
  8. TB, caused by Mycobacterium tuberculosis (MTB), is one of the major global infectious diseases. For the pandemic control, early diagnosis with sensitive and specific methods is fundamental. With the advent of bio...

    Authors: Romel Calero, Mayelin Mirabal, Jesús Bouza, María V Guzmán, Humberto Carrillo, Yamilé López, Mohd Nor Norazmi, Maria E Sarmiento and Armando Acosta
    Citation: BMC Immunology 2013 14(Suppl 1):S9
  9. The proteoliposome derived from Vibrio cholerae O1 (PLc) is a nanoscaled structure obtained by a detergent extraction process. Intranasal (i.n) administration of PLc was immunogenic at mucosal and systemic level ...

    Authors: Reinaldo Acevedo, Adriana Callicó, Yisabel Aranguren, Caridad Zayas, Yolanda Valdés, Oliver Pérez, Luis García, Valerie A Ferro and José Luis Pérez
    Citation: BMC Immunology 2013 14(Suppl 1):S10
  10. The development of a new tuberculosis (TB) vaccine has become one of the main objectives of the scientific community. Protein antigens have been widely explored as subunit TB vaccines, however lipid antigens c...

    Authors: María de los Angeles García, Reinier Borrero, Reynel Marrón, María E Lanio, Lien Canet, Oscar Otero, Ramlah Kadir, Siti Suraiya, Caridad Zayas, Yamilé López, Mohd Nor Norazmi, Maria E Sarmiento and Armando Acosta
    Citation: BMC Immunology 2013 14(Suppl 1):S11
  11. Proteoliposomes purified from the Outer Membrane of Neisseria meningitidis B, have been successfully used as core for adjuvants and vaccine formulations. We have tried to increase their structural definition and ...

    Authors: Beatriz Tamargo, Yanet Márquez, Wendy Ramírez, Bárbara Cedré, Manuel Fresno and Gustavo Sierra
    Citation: BMC Immunology 2013 14(Suppl 1):S12
  12. Mycobacterium smegmati s (Ms) is a nonpathogenic mycobacteria of rapid growth, which shares many characteristics with Mycobacterium tuberculosis (MTB), the major causative agent of tuberculosis. MTB has several c...

    Authors: Reinier Borrero, María de los A García, Liem Canet, Caridad Zayas, Fátima Reyes, Jorge L Prieto, Juan F Infante, María E Lanio, Ramlah Kadir, Yamilé López, María E Sarmiento, Mohd Nor Norazmi and Armando Acosta
    Citation: BMC Immunology 2013 14(Suppl 1):S13

Annual Journal Metrics

  • Citation Impact
    3.594 - 2-year Impact Factor (2021)
    3.857 - 5-year Impact Factor (2021)
    0.924 - SNIP (Source Normalized Impact per Paper)
    0.828 - SJR (SCImago Journal Rank)

    50 days to first decision for all manuscripts (Median)
    157 days to first decision for reviewed manuscripts only (Median)

    532,299 Downloads (2021)
    256 Altmetric mentions (2021) 

Sign up for article alerts and news from this journal